Structure-immunogenicity relationships of therapeutic proteins

Pharmaceutical Research

Volumn 21, Issue 6, 2004, Pages 897-903

  Hermeling, Suzanne ^a,b   Crommelin, Daan J A ^a   Schellekens, Huub ^b   Jiskoot, Wim ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

aggregation; animal models; immunogenicity; protein structure; therapeutic proteins

Indexed keywords

AMINO ACID; ANTIBODY; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; RECOMBINANT PROTEIN;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; DECOMPOSITION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INCIDENCE; MODEL; NONHUMAN; OXIDATION; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRANSGENIC ANIMAL;

ANIMALS; HUMANS; IMMUNE TOLERANCE; NETHERLANDS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042761213     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000029275.41323.a6     Document Type: Review

References (43)

1. G. Schernthaner. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155-165 (1993).
2. G. Walsh. Pharmaceutical biotechnology products approved within the European Union. Eur. J. Pharm. Biopharm. 55:3-10 (2003).
3. F. Adair and D. Ozanne. The immunogenicity of therapeutic proteins. BioPharm February:30-36 (2002).
4. H. F. Bunn. Drug-induced autoimmune red-cell aplasia. N. Engl. J. Med. 346:522-523 (2002).
5. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475 (2002).
6. S. K. Gershon, H. Luksenburg, T. R. Cote, and M. M. Braun. Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 346:1584-1586 (2002).
7. M. F. Bachmann, U. H. Rohrer, T. M. Kundig, K. Burki, H. Hengartner, and R. M. Zinkernagel. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451 (1993).
8. N. R. Pritchard and K. G. Smith. B cell inhibitory receptors and autoimmunity. Immunology 108:263-273 (2003).
9. B. Chackerian, P. Lenz, D. R. Lowy, and J. T. Schiller. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 169:6120-6126 (2002).
10. F. Matesanz and A. Alcina. Induction of autoantibodies to different interleukin-2 allotypes. J. Autoimmun. 12:221-227 (1999).
11. M. Van Ghelue, U. Moens, S. Bendiksen, and O. P. Rekvig. Autoimmunity to nucleosomes related to viral infection: a focus on hapten-carrier complex formation. J. Autoimmun. 20:171-182 (2003).
12. J. L. Ottesen, P. Nilsson, J. Jami, D. Weilguny, M. Duhrkop, D. Bucchini, S. Havelund, and J. M. Fogh. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1185 (1994).
13. A. V. Palleroni, A. Aglione, M. Labow, M. J. Brunda, S. Pestka, F. Sinigaglia, G. Garotta, J. Alsenz, and A. Braun. Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res. 17:S23-S27 (1997).
14. T. A. Stewart, P. G. Hollingshead, S. L. Pitts, R. Chang, L. E. Martin, and H. Oakley. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol. Biol. Med. 6:275-281 (1989).
15. C. M. Zwickl, K. S. Cocke, R. N. Tamura, L. M. Holzhausen, G. T. Brophy, P. H. Bick, and D. Wierda. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam. Appl. Toxicol. 16:275-287 (1991).
16. A. Braun, L. Kwee, M. A. Labow, and J. Alsenz. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14:1472-1478 (1997).
17. M. Brickelmaier, P. S. Hochman, R. Baciu, B. Chao, J. H. Cuervo, and A. Whitty. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J. Immunol. Methods 227:121-135 (1999).
18. E. Hochuli. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J. Interferon Cytokine Res. 17:S15-S21 (1997).
19. P. Fireman, S. E. Fineberg, and J. A. Galloway. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care 5:119-125 (1982).
20. S. E. Fineberg, J. A. Galloway, and N. S. Fineberg, J. Goldman. Effects of species of origin purification levels and formulation on insulin immunogenicity. Diabetes 32:592-599 (1983).
21. X. Du and J. G. Tang. Effects of deleting A19 tyrosine from insulin. Biochem. Mol. Biol. Int. 44:507-513 (1998).
22. H. Lis and N. Sharon. Protein glycosylation. Structural and functional aspects. Eur. J. Biochem. 218:1-27 (1993).
23. C. F. Goochee and T. Monica. Environmental effects on protein glycosylation. Biotechnology (N Y) 8:421-427 (1990).
24. J. G. Gribben, S. Devereux, N. S. Thomas, M. Keim, H. M. Jones, A. H. Goldstone, and D. C. Linch. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335:434-437 (1990).
25. G. R. Adolf, I. Kalsner, H. Ahorn, I. Maurer-Fogy, and K. Cantell. Natural human interferon-alpha 2 is O-glycosylated. Biochem. J. 276:511-518 (1991).
26. P. Kontsek, H. Liptakova, and E. Kontsekova. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. Acta Virol. 43:63-70 (1999).
27. C. B. Colby, M. Inoue, M. Thompson, and Y. H. Tan. Immunologie differentiation between E. coli and CHO cell-derived recombinant and natural human beta-interferons. J. Immunol. 133: 3091-3095 (1984).
28. D. Bhadra, S. Bhadra, P. Jain, and N. K. Jain. Pegnology: a review of PEG-ylated systems. Pharmazie 57:5-29 (2002).
29. F. F. Davis. The origin of pegnology. Adv. Drug Deliv. Rev. 54:457-458 (2002).
30. F. M. Veronese. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22:405-417 (2001).
31. K. Rajender Reddy, M. W. Modi, and S. Pedder. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54:571-586 (2002).
32. C. M. Perry and B. Jarvis. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 61:2263-2288 (2001).
33. K. D. Hinds and S. W. Kim. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54:505-530 (2002).
34. D. C. Robbins, S. M. Cooper, S. E. Fineberg, and P. M. Mead. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838-841 (1987).
35. J. C. Ryff. Clinical investigation of the immunogenicity of interferon-alpha 2a. J. Interferon Cytokine Res. 17:S29-S33 (1997).
36. W. V. Moore and P. Leppert. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51:691-697 (1980).
37. M. Xie and R. L. Schowen. Secondary structure and protein deamidation. J. Pharm. Sci. 88:8-13 (1999).
38. M. C. Lai and E. M. Topp. Solid-state chemical stability of proteins and peptides. J. Pharm. Sci. 88:489-500 (1999).
39. J. L. Cleland, M. F. Powell, and S. J. Shire. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10:307-377 (1993).
40. H. T. Wright. Sequence and structure determinants of the non-enzymatic deamidation of asparagine and glutamine residues in proteins. Protein Eng. 4:283-294 (1991).
41. W. Chen, N. J. Ede, D. C. Jackson, J. McCluskey, and A. W. Purcell. CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 157:1000-1005 (1996).
42. H. Schellekens. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1:457-462 (2002).
43. R. E. Chance, E. P. Kroeff, J. A. Hoffmann, and B. H. Frank. Chemical, physical, and biologic properties of biosynthetic human insulin. Diabetes Care 4:147-154 (1981).